JY
TRVI icon

Jeff Yass’s Trevi Therapeutics TRVI Stock Holding History

Jeff Yass’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
23,350
-204,338
-90% -$2.97M ﹤0.01% 10223
2026
Q1 		$2.72M Sell
227,688
-597,860
-72% -$6.69M ﹤0.01% 5483
2025
Q4 		$10.3M Sell
825,548
-775,194
-48% -$8.96M ﹤0.01% 2999
2025
Q3 		$14.6M Buy
1,600,742
+1,473,157
+1,155% +$11M ﹤0.01% 2528
2025
Q2 		$698K Sell
127,585
-153,514
-55% -$955K ﹤0.01% 8361
2025
Q1 		$1.77M Buy
281,099
+240,491
+592% +$1.15M ﹤0.01% 5806
2024
Q4 		$167K Buy
40,608
+230
+0.6% +$736 ﹤0.01% 10923
2024
Q3 		$135K Buy
+40,378
New +$120K ﹤0.01% 10837
2024
Q1 		– Sell
-17,207
Closed -$23.1K – 13345
2023
Q4 		$23.1K Buy
+17,207
New +$26.1K ﹤0.01% 11947
2023
Q3 		– Sell
-11,571
Closed -$27.7K – 13007
2023
Q2 		$27.7K Sell
11,571
-16,095
-58% -$40.6K ﹤0.01% 11548
2023
Q1 		$51.2K Buy
+27,666
New +$62.6K ﹤0.01% 11695
2021
Q1 		– Sell
-14,828
Closed -$36K – 12869
2020
Q4 		$36K Buy
+14,828
New +$48K ﹤0.01% 10816

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Jeff Yass's TRVI Position: Q2 2026 in Review

Jeff Yass reduced its Trevi Therapeutics (TRVI) stake by 90% in Q2 2026, selling an estimated $2.97M and leaving 23,350 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #10223.

Jeff Yass first reported a position in TRVI in Q4 2020 and has held it in 12 quarters since. The position peaked at $14.6M in Q3 2025. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Jeff Yass held 23,350 shares of Trevi Therapeutics worth $435K as of Q2 2026.
  • Jeff Yass sold 204,338 Trevi Therapeutics shares in Q2 2026, an estimated $2.97M.
  • Trevi Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10223 holding.
  • Jeff Yass first reported a position in Trevi Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Jeff Yass's Trevi Therapeutics position peaked at $14.6M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.